









Markets
/
Stocks
/
nasdaq-scnx
/

Scienture Holdings Inc

SCNX

0.893USD

+0.004+0.45%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

14.41MMarket Cap

LossP/E TTM



Scienture Holdings Inc

0.893

+0.004+0.45%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a good stock market performance, the company shows weak fundamentals and technicals, which don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

128 / 175

Overall Ranking

529 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Scienture Holdings, Inc., formerly TRxADE Health, Inc., is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the United States. It operates through Scienture, LLC and Integra Pharma Solutions, LLC. Scienture, LLC is a branded specialty pharmaceutical company. Its assets in development are across therapeutics areas, indications and cater to different market segments. Its products include SCN - 102 (Cardiovascular), SCN - 104 (CNS-Pain), SCN - 105 (CNS), SCN - 106 (Cardiovascular) and SCN - 107 (Pain). Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Its expertise in the distribution of products extends to all healthcare markets including government organizations, hospitals, clinics, and independent pharmacies nationwide.

Growing

The company is in a growing phase, with the latest annual income totaling USD 136.64K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 9.07M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is -0.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.45M shares, increasing 0.01% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 14.57K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 4.85, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 266.46%.

Score

Industry at a Glance

Previous score

4.85

Change



Financials

2.06

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.17

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.82

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.15

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.06

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.06, which is 341.69% below the recent high of -0.28 and -1935.14% above the recent low of -1.27.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.87, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.10 and the support level at 0.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.87

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.051

Neutral

RSI(14)

34.282

Neutral

STOCH(KDJ)(9,3,3)

21.484

Sell

ATR(14)

0.086

High Vlolatility

CCI(14)

-32.145

Neutral

Williams %R

79.701

Sell

TRIX(12,20)

-2.181

Sell

StochRSI(14)

52.164

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.917

Sell

MA10

0.907

Sell

MA20

0.949

Sell

MA50

1.488

Sell

MA100

1.262

Sell

MA200

2.431

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 32.07%, representing a quarter-over-quarter decrease of 5.51%. The largest institutional shareholder is The Vanguard, holding a total of 14.57K shares, representing 0.07% of shares outstanding, with 57.79% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Hariharan (Shankar Ph.D.)

2.37M

Mani (Narasimhan)

1.42M

Ajjarapu (Surendra K)

210.10K

Patel Prashant

176.69K

Doshi (Mayur Mansukhlal)

66.45K

Armistice Capital LLC

65.50K

+127.04%

Fell (Donald G.)

35.16K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 3.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.